4.19
price down icon0.48%   -0.02
after-market After Hours: 4.20 0.010 +0.24%
loading
Opthea Limited Adr stock is traded at $4.19, with a volume of 4,224. It is down -0.48% in the last 24 hours and down -6.47% over the past month. Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.
See More
Previous Close:
$4.21
Open:
$4.22
24h Volume:
4,224
Relative Volume:
0.17
Market Cap:
$652.16M
Revenue:
$117.10K
Net Income/Loss:
$-161.61M
P/E Ratio:
-1.7255
EPS:
-2.4283
Net Cash Flow:
-
1W Performance:
-8.52%
1M Performance:
-6.47%
6M Performance:
+22.59%
1Y Performance:
+140.11%
1-Day Range:
Value
$4.19
$4.2379
1-Week Range:
Value
$4.19
$4.60
52-Week Range:
Value
$1.63
$5.45

Opthea Limited Adr Stock (OPT) Company Profile

Name
Name
Opthea Limited Adr
Name
Phone
-
Name
Address
-
Name
Employee
34
Name
Twitter
Name
Next Earnings Date
2024-09-04
Name
Latest SEC Filings
Name
OPT's Discussions on Twitter

Opthea Limited Adr Stock (OPT) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-08-22 Initiated H.C. Wainwright Buy
Apr-26-22 Initiated SVB Leerink Outperform
Nov-17-20 Initiated Citigroup Buy
Nov-11-20 Initiated Oppenheimer Outperform
Nov-11-20 Initiated SVB Leerink Outperform
Nov-11-20 Initiated Truist Buy
View All

Opthea Limited Adr Stock (OPT) Latest News

pulisher
Nov 04, 2024

Opthea to Participate in November Investor Conferences - The Manila Times

Nov 04, 2024
pulisher
Nov 01, 2024

Opthea Limited Strengthens Leadership and Advances AMD Treatment - TipRanks

Nov 01, 2024
pulisher
Oct 19, 2024

FY2025 EPS Estimates for Opthea Lifted by Leerink Partnrs - Defense World

Oct 19, 2024
pulisher
Oct 16, 2024

OPTOpthea Limited American Depositary Shares Latest Stock News & Market Updates - StockTitan

Oct 16, 2024
pulisher
Oct 16, 2024

Is Opthea Limited (OPT) the Penny Stock with the Biggest Upside Potential According to Analysts? - Insider Monkey

Oct 16, 2024
pulisher
Oct 16, 2024

Opthea Files Notice of Annual General Meeting - The Manila Times

Oct 16, 2024
pulisher
Oct 12, 2024

Opthea Ltd stock soars to 52-week high, touches $4.95 - Investing.com India

Oct 12, 2024
pulisher
Oct 12, 2024

Opthea Ltd stock soars to 52-week high, touches $4.95 By Investing.com - Investing.com South Africa

Oct 12, 2024
pulisher
Oct 10, 2024

Opthea Wet AMD Program to be Presented at Innovate Retina - The Manila Times

Oct 10, 2024
pulisher
Oct 08, 2024

Opthea Appoints Chief Medical Officer and Chief Financial Officer as Company Prepares for Phase 3 Topline Data Readouts in 2025 - The Manila Times

Oct 08, 2024
pulisher
Oct 07, 2024

Opthea Limited Announces Chief Financial Officer Changes - Marketscreener.com

Oct 07, 2024
pulisher
Sep 30, 2024

Opthea to Participate in the UBS Virtual Ophthalmology Day 2024 - The Manila Times

Sep 30, 2024
pulisher
Sep 30, 2024

Opthea Advances Retinal Disease Treatments - TipRanks

Sep 30, 2024
pulisher
Sep 26, 2024

Opthea Advances nAMD Treatment with Sozinibercept - TipRanks

Sep 26, 2024
pulisher
Sep 23, 2024

Opthea Joins the S&P/ASX 300 Index - Morningstar

Sep 23, 2024
pulisher
Sep 19, 2024

Opthea Limited (NASDAQ:OPT) Shares Sold by Victory Capital Management Inc. - Defense World

Sep 19, 2024
pulisher
Sep 18, 2024

EX-99.1 - SEC.gov

Sep 18, 2024
pulisher
Sep 18, 2024

Opthea Advances Toward Sozinibercept Commercialization - TipRanks

Sep 18, 2024
pulisher
Sep 10, 2024

Opthea’s Sozinibercept Eyes Breakthrough in AMD Therapy - TipRanks

Sep 10, 2024
pulisher
Sep 07, 2024

FY2025 EPS Estimates for Opthea Limited Boosted by HC Wainwright (NASDAQ:OPT) - Defense World

Sep 07, 2024
pulisher
Sep 06, 2024

Research Analysts Set Expectations for Opthea Limited’s FY2029 Earnings (NASDAQ:OPT) - Defense World

Sep 06, 2024
pulisher
Sep 05, 2024

Opthea Prepares for Phase 3 Results with Leadership Revamp - TipRanks

Sep 05, 2024
pulisher
Sep 05, 2024

Opthea Announces Executive Leadership Changes and Senior Hires - StockTitan

Sep 05, 2024
pulisher
Sep 04, 2024

Opthea (NASDAQ:OPT) Given New $12.00 Price Target at HC Wainwright - Defense World

Sep 04, 2024
pulisher
Sep 03, 2024

Opthea Limited Showcases Innovations at Investor Conferences - TipRanks

Sep 03, 2024
pulisher
Aug 30, 2024

Opthea Limited: Revenues Up, Losses Widen - TipRanks

Aug 30, 2024
pulisher
Aug 30, 2024

Opthea Reports Full-Year Financial Results and Business Updates - Morningstar

Aug 30, 2024
pulisher
Aug 08, 2024

Opthea to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference, August 15, 2024 - Morningstar

Aug 08, 2024
pulisher
Aug 08, 2024

Opthea Limited Showcases at Ophthalmology Event - TipRanks

Aug 08, 2024
pulisher
Jul 17, 2024

Opthea forms global medical advisory board for retinal diseases - Investing.com India

Jul 17, 2024
pulisher
Jul 17, 2024

Opthea Welcomes International Retina Thought Leaders to Join Its Medical Advisory Board - StockTitan

Jul 17, 2024
pulisher
Jul 14, 2024

Why Atturra, Bravura, Core Lithium, and Opthea shares are racing higher today - The Motley Fool

Jul 14, 2024
pulisher
Jul 09, 2024

Opthea’s Sozinibercept Shows Promise for Wet AMD - TipRanks

Jul 09, 2024
pulisher
Jul 09, 2024

Opthea Announces Publication on VEGF-C and D Signaling Pathways as Potential Targets for Treatment of Wet AMD - StockTitan

Jul 09, 2024
pulisher
Jul 05, 2024

Opthea (NASDAQ:OPT) Shares Down 0.8% - Defense World

Jul 05, 2024
pulisher
Jul 02, 2024

Opthea Data for OPT-302 in Patients with Polypoidal Choroidal Vasculopathy (PCV) Presented at Angiogenesis 2022 - The Globe and Mail

Jul 02, 2024
pulisher
Jun 29, 2024

Opthea To Present at SVB Leerink Global Healthcare Conference - The Globe and Mail

Jun 29, 2024
pulisher
Jun 27, 2024

Opthea strengthens its Board of Directors - Quantisnow

Jun 27, 2024
pulisher
Jun 27, 2024

Optiva Wins Prestigious "Enterprise eSIM Solution of the Year" Award - GlobeNewswire Inc.

Jun 27, 2024
pulisher
Jun 18, 2024

Opthea A$55.0m (US$36.9m¹) Retail Entitlement Offer Opens - Morningstar

Jun 18, 2024
pulisher
Jun 15, 2024

Opthea raises $113.2 million to fund eye drug development - The Pharma Letter

Jun 15, 2024
pulisher
Jun 13, 2024

Opthea Successfully Completes Placement and Institutional Component of Entitlement Offer Raising A$171.5 million (US$113.2m¹) - Morningstar

Jun 13, 2024
pulisher
May 31, 2024

Opthea LimitedADR (OPT) Price Target Increased by 9.06% to 5.95 - MSN

May 31, 2024
pulisher
May 30, 2024

Market Insight: Opthea Limited ADR (OPT)'s Notable Drop, Closing at 3.00 – DWinneX - The Dwinnex

May 30, 2024
pulisher
May 28, 2024

2 Stocks Under $10 Wall Street Says Are 'Strong Buys' - Barchart

May 28, 2024
pulisher
May 28, 2024

Opthea (NASDAQ:OPT) Shares Down 0.6% - Defense World

May 28, 2024
pulisher
Apr 05, 2024

Opthea to Participate in the 23ʳᵈ Annual Needham Virtual Healthcare Conference By Investing.com - Investing.com South Africa

Apr 05, 2024
pulisher
Apr 03, 2024

Opthea appoints new director and audit chair By Investing.com - Investing.com

Apr 03, 2024
pulisher
Mar 24, 2024

11 Best ASX Stocks To Buy Now - Yahoo Finance

Mar 24, 2024
pulisher
Feb 19, 2024

Opthea Limited completes enrollment for 1 of 2 Phase 3 sozinibercept (OPT-302) trials - Optometry Times

Feb 19, 2024
pulisher
Feb 05, 2024

10 Best Australian Stocks To Buy - Yahoo Finance

Feb 05, 2024

Opthea Limited Adr Stock (OPT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Cap:     |  Volume (24h):